KITE PHARMA, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.kitepharma.com
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)
Phase 2
Completed
- Conditions
- Relapsed/Refractory Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 105
- Registration Number
- NCT02601313
- Locations
- 🇺🇸
Loyola University Chicago, Maywood, Illinois, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
Phase 1
Completed
- Conditions
- Primary Mediastinal B-cell Lymphoma (PMBCL)Transformed Follicular Lymphoma (TFL)High Grade B-cell Lymphoma (HGBCL)Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B-Cell Lymphoma
- Interventions
- Biological: Axicabtagene Ciloleucel
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 307
- Registration Number
- NCT02348216
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of California Los Angeles (UCLA), Santa Monica, California, United States
🇨🇦Princess Margaret, Toronto, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath